Background: A needs assessment for patients with hidradenitis suppurativa (HS) will support advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy.

Summary Background A core outcomes set (COS) is an agreed minimum set of outcomes that should be measured and reported in all clinical trials for a specific condition. Hidradenitis suppurativa (HS) has no agreed-upon COS. A central aspect in the COS development process is to identify a set of candidate outcome domains from a long list of items. Our long list had been developed from patient interviews, a systematic review of the literature and a healthcare professional survey, and initial votes had been cast in two e-Delphi surveys. In this manuscript, we describe two in-person consensus meetings of Delphi participants designed to ensure an inclusive approach to generation of domains from related items. Objectives To consider which items from a long list of candidate items to exclude and which to cluster into outcome domains. Methods The study used an international and multistakeholder approach, involving patients, dermatologists, surgeons, the pharmaceutical industry and medical regulators. The study format was a combination of formal presentations, small group work based on nominal group theory and a subsequent online confirmation survey. Results Forty-one individuals from 13 countries and four continents participated. Nine items were excluded and there was consensus to propose seven domains: disease course, physical signs, HS-specific quality of life, satisfaction, symptoms, pain and global assessments. Conclusions The HISTORIC consensus meetings I and II will be followed by further e-Delphi rounds to finalize the core domain set, building on the work of the in-person consensus meetings.

No abstract

alveolar capillaries, 2 endothelial cells of kidney glomeruli, 3 brain blood vessels, 4 colonic mucosa 5 and skin. 6 Our immunohistochemical study represents a straightforward means of linking SARS-CoV-2 infection and endothelium.The presence of the virus in eccrine glands suggests sweat as a source of contagion, but this should be interpreted with caution. Given the similarities of SARS-CoV and SARS-CoV-2, it is worth mentioning that in a 2004 study of four autopsied patients with SARS, Ding et al. 7 found SARS-CoV nucleoprotein and RNA by immunohistochemistry and in situ hybridization, respectively, in a wide array of tissues, including sweat glands, intestine and kidney. They speculated accordingly the possibility of virus transmission through faeces, urine and sweat. A number of viruses, like hepatitis C virus, are known to replicate in sweat glands and keratinocytes; this could be investigated in sweat obtained by pilocarpine stimulation. 8Acknowledgments: We would like to thank Sandra P erez-Buira, PhD, who optimized and performed the immunohistochemical study.

Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry To the Editor: Hidradenitis suppurativa (HS) patients may be at increased risk of severe COVID-19 and poor outcomes due to comorbidities and biologic treatment. 1 COVID-19 cases in HS patients were reported in the Global Hidradenitis Suppurativa COVID-19 Registry (https://hscovid.ucsf.edu/) from April 5, 2020, to February 2, 2021. 1 Eligible cases had confirmed diagnosis of HS by a health care provider (HCP) or screening questions and COVID-19 diagnosis by an HCP. Comparisons were performed using the Fisher's exact or Pearson 2 test. Multivariable logistic regression was used to predict outcomes based on biologic use, adjusting for demographic features and comorbidities.